Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

Bristol Myers Squibb presented clinical data up to five years supporting the long-term efficacy and safety of Camzyos (mavacamten). The update reinforces durability of benefits rather than introducing new negative findings, which is modestly supportive for sentiment around the drug and BMY’s pipeline.